Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...
An update to the guidelines for urticaria management was published, involving collaboration from various international ...
New biologics, precision diagnostics, and AI are reshaping care for rare allergies — from eosinophilic esophagitis to drug ...
Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when ...
Seven abstracts represent data across migraine, childhood-onset epilepsy and multiple system atrophy (MSA), highlighting Lundbeck's biology-driven approach to developing treatments for serious brain ...
MastCURe, a high-profile research consortium, has been awarded EUR1.3M in funding from the Eureka Eurostars program. The collaboration comprising Allegria Therapeutics, Cube Biotech, and the ...
Phase 1 Study Will Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EDP-978 in Healthy VolunteersTopline Data Expected in Q4 2026WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta ...
UCB will present additional studies and data analyses highlighting UCB's ongoing commitment to improving outcomes for people living with gMGTwo studies ...
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
Seasonal allergies affect millions. Experts share strategies to prepare now and make spring allergy season more manageable.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results